Actively Recruiting
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
Led by UCB Biopharma SRL · Updated on 2026-03-27
40
Participants Needed
18
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
CONDITIONS
Official Title
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant is between 12 and less than 18 years old at the time of consent and at Tanner stage 2 or higher for the first 8 participants, then includes participants aged 9 to less than 18 years at Tanner stage 2 or higher
- Diagnosis of hidradenitis suppurativa for at least 6 months before the baseline visit
- Moderate to severe hidradenitis suppurativa with at least 5 inflammatory lesions (abscesses and nodules) at screening and baseline visits
- Hidradenitis suppurativa lesions in at least 2 different body areas, with at least one area at Hurley Stage II or III at screening and baseline visits
- History of inadequate response to a course of systemic antibiotics for hidradenitis suppurativa
- Weight of at least 30 kg at screening visit
You will not qualify if you...
- Draining tunnel count greater than 20 at screening or baseline visits
- Primary failure (no response within 12 weeks) to one or more IL-17 biologic response modifiers or to more than one biologic response modifier other than IL-17 modifiers
- Previous participation in this study or prior treatment with bimekizumab
- History or symptoms suggestive of inflammatory bowel disease
- Active tuberculosis unless successfully treated or latent tuberculosis unless prophylactically treated
- Active infection or history of serious, chronic, opportunistic, or unusually severe infections
- Receipt of prohibited drugs outside specified timeframes or prohibited concomitant treatments
- Presence of active suicidal thoughts or positive suicide behavior
- Diagnosis of severe depression within 6 months prior to screening
- Psychiatric inpatient hospitalization within 1 year before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Hs0006 50175
Phoenix, Arizona, United States, 85006
Actively Recruiting
2
Hs0006 50708
Roseville, California, United States, 95661
Actively Recruiting
3
Hs0006 50684
Sacramento, California, United States, 95815
Actively Recruiting
4
Hs0006 50707
Washington D.C., District of Columbia, United States, 20010
Actively Recruiting
5
Hs0006 50199
Miami, Florida, United States, 33136
Actively Recruiting
6
Hs0006 50178
Clarkston, Michigan, United States, 48346
Actively Recruiting
7
Hs0006 50710
Fort Gratiot, Michigan, United States, 48059
Actively Recruiting
8
Hs0006 50711
Troy, Michigan, United States, 48084
Actively Recruiting
9
Hs0006 50712
New York, New York, United States, 10023
Actively Recruiting
10
Hs0006 50706
Chapel Hill, North Carolina, United States, 27516
Actively Recruiting
11
Hs0006 50202
Fairborn, Ohio, United States, 45324
Actively Recruiting
12
Hs0006 50201
Arlington, Texas, United States, 76011
Actively Recruiting
13
Hs0006 40326
Berlin, Germany
Actively Recruiting
14
Hs0006 40747
Mainz, Germany
Actively Recruiting
15
Hs0006 40625
Warsaw, Poland
Actively Recruiting
16
Hs0006 40761
Warsaw, Poland
Actively Recruiting
17
Hs0006 40095
Wroclaw, Poland
Actively Recruiting
18
Hs0006 40845
Wroclaw, Poland
Actively Recruiting
Research Team
U
UCB Cares
CONTACT
U
UCB Cares
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here